Nut and Seed Butters — Body Handbook

Food · §318

Nut and Seed Butters

The jar in your fridge is probably doing less than you think it is. Plain ground peanuts, almonds, cashews, sesame, or sunflower seeds are one of the better things you can spread on bread — real protein, the right kind of fat, micronutrients most diets undersupply. The Skippy-and-Jif version sitting next to them in the supermarket, with added sugar and palm oil stirred in to stop the oil from separating, is a different food. And even the good jar is not a whole almond: the moment you grind a nut into butter, you forfeit some of the satiety and most of the "a calorie isn't a calorie" reprieve the whole nut earned in the famous trials.

Do · Daily Evidence Moderate Chapter Food

A two-ingredient nut or seed butter beats butter, margarine, jam, and chocolate-hazelnut spread on every nutrient that matters: lower-saturated fat, more protein, more magnesium and vitamin E, a flatter blood-sugar curve at breakfast. None of those are headline transformations — small, real, would-show-up-on-a-blood-test-not-in-a-mirror. The win is mostly upstream of the spoon: picking the jar that lists one or two ingredients instead of six.

A whole almond is a structured thing. About half its fat sits inside intact plant cell walls, and a meaningful fraction of those walls survive your chewing and digestion — fecal-recovery studies find recognisable almond fragments coming out the other end, lipid still locked inside. The body never collects the calories the label claims. Roasted whole almonds deliver about 19% fewer calories than the nutrition label says; whole raw almonds, 25% fewer Gebauer 2016, Novotny 2012.

The moment you grind a nut into butter, that reprieve disappears. Cell walls rupture, lipid floods out, and the calorie count on the jar becomes accurate down to the gram. The same 30 g of almonds is roughly 50 absorbed calories as a handful and roughly 195 as a tablespoon of butter — a quiet ~25% tax most readers never know they're paying. Chewing matters for fullness too: in Cassady 2009, healthy adults who chewed almonds 40 times before swallowing reported less hunger and different gut-hormone responses than those who chewed only 10 times. Butter skips the chewing step. You still get the satiety advantage that fat and protein give over carbohydrate — butter on toast beats jam on toast every time — but the chewing-mediated piece of that signal is gone.

What butter does keep, in full: it blunts the blood-sugar spike from whatever carbohydrate you put it on, it nudges your blood-lipid panel in the right direction over weeks to months, and it delivers minerals most diets are short on. Two tablespoons of peanut butter add roughly 7 grams of protein and about 14% of a day's magnesium; the same amount of tahini delivers about a tenth of a day's calcium plus sesame lignans that nudge cholesterol downward; almond butter brings about half a day's vitamin E. These are not glamorous numbers, but for the typical Western diet they are exactly the gaps that need filling.

What the trials actually show

The lipid evidence is unambiguous. Across 61 controlled feeding trials, regular nut intake drops total cholesterol, LDL, and apoB by clinically meaningful amounts, with the effect proportional to dose up to about 60 g a day Del Gobbo 2015. The trials that used ground nut or nut paste produced the same direction and roughly the same magnitude as the ones using whole nuts — when the question is "does the fat in this food displace the saturated fat your liver makes cholesterol out of," form barely matters.

The blood-sugar evidence is just as clean for the moment of eating. Eat almonds with a carbohydrate meal and the glucose spike flattens in a dose-response fashion Josse 2007. Almond butter does the same job at the meal you eat it with — but only whole almonds keep blunting your blood sugar at the next meal too, and across the day Mori 2011. The slower-digesting, cell-wall-protected fat in the whole nut behaves like a sustained brake; the butter behaves like a single press.

The longevity case is built almost entirely on whole nuts. PREDIMED randomised about 7,400 high-risk adults to a Mediterranean diet plus 30 grams of mixed nuts a day or a low-fat control, and the nut arm cut major cardiovascular events by roughly 28% over five years Estruch 2018. The Nurses' Health and Health Professionals cohorts (over 100,000 adults followed for decades) found people eating a handful of nuts most days had about 20% lower all-cause mortality, with a consistent dose-response Bao 2013, Aune 2016.

The honest catch — and worth knowing before someone uses peanut butter as their proof: in the half-million-adult NIH-AARP cohort, whole peanuts and tree nuts cut mortality the way the other studies predict, and peanut butter did not Luu 2015. The most plausible reason isn't that nut butter is bad; it's that the typical American peanut-butter exposure is a sugared, palm-oil-stabilized spread on white bread with jelly, and the refined-carb context cancels the nut benefit at the population level. A separate analysis in women found peanut butter intake tracked with lower type-2-diabetes incidence the way whole nuts do Jiang 2002 — different cohort, different exposure pattern, different answer. The lesson is not that peanut butter is condemned; it is that the cohort signal depends entirely on which jar people are actually buying.

How to do this well

Most of the work is at the store, not at the table. The product that matches the food in the trials is one or two ingredients on the back of the jar.

Read the ingredient list. "Peanuts" or "peanuts, salt" is the food. "Peanuts, sugar, palm oil, salt, hydrogenated vegetable oil" is a different product. Mainstream commercial peanut butter routinely carries 2–3 grams of added sugar per 2-tablespoon serving — small per spoon, real over a year.
Aim for one to two tablespoons most days (about 16 to 32 grams) — on bread or oats or fruit, not from the jar. The trials that found the cardiovascular benefit used about a handful's worth.
Pair it with the carbohydrate. Butter on toast, stirred into oats, or with fruit blunts the blood-sugar spike from those foods. Eaten alone, the spike-flattening benefit is wasted.
Stir the oil layer, refrigerate after opening, scoop with a measuring spoon. The visible oil is the nut's own unsaturated fat — it's a feature, not a defect. Brands that don't separate have added something to stop the separating.

The "natural" label on the front of the jar is not regulated and means nothing. The ingredient list on the back is the only thing that does.

What most people get wrong

"Nut butter is basically the same as eating nuts." Same nutrients, different food. The famous trial finding — that you can add a daily handful of nuts to your diet without gaining the weight the math says you should — runs on cell walls keeping fat trapped inside the nut. Grind the nut and you erase that mechanism. A 30-gram serving of almonds is around 50 calories absorbed when you eat them whole, around 195 calories absorbed when you eat them as butter Gebauer 2016. If you can chew, the whole nut wins.

"The oil floating on top means it's gone bad." No. That's the nut's own oil, separated out because nothing was added to keep it mixed in. Brands without that layer have added a stabilizer — usually palm oil or fully hydrogenated vegetable oil — precisely to keep the oil from floating up. Stir it back in, refrigerate, eat. If anything, the visible oil layer is a sign the product is closer to plain ground nuts.

"Natural peanut butter is healthier." The word natural on a food label is not a regulated term. A jar can say "all natural" on the front and still list sugar and palm oil on the back. Flip the jar over.

Where this goes wrong

Three failures, in order of how often they happen.

The wrong jar. A sugared, palm-oil-stabilized peanut butter on white bread is closer to a cookie than to the food the trials studied. Most of this entry is upstream of the spoon — it lives in which product you picked at the store. If you pick the six-ingredient jar, the lipid and glucose benefits do not arrive.

Spoon-from-jar grazing. A tablespoon of almond butter is about 100 calories; a casual spoon you didn't measure is closer to two or three of those. Butter is highly palatable, low-effort to eat, and absorbed in full. The thing that makes a handful of whole nuts hard to overeat — the chewing, the time, the fact that some of the calories pass through — does not protect you here. Portion by tablespoon, not by spoon-feel.

Replacing whole nuts with butter for convenience. If you're getting your nut intake from butter because it's easier than carrying almonds, you're trading away the satiety, the energy-absorption discount, and the next-meal blood-sugar benefit Cassady 2009, Mori 2011. Butter is the spread; whole nuts are the snack. When you can chew, chew.

When to be careful

Aflatoxin in peanut products. The mould Aspergillus flavus contaminates peanut crops grown or stored hot and humid, and its toxin aflatoxin B1 is a known liver carcinogen Williams 2004. US commercial peanut butter is tested against an FDA action limit of 20 parts per billion and almost always sits comfortably under it; the cancer-risk contribution in the US food supply is small. Storage matters too: keep the jar somewhere cool and dry, not in a hot cupboard. The substantial human-health burden from aflatoxin sits in regions with looser regulation and informal supply chains Wu 2018.

Cadmium in sunflower-seed butter. Sunflowers are unusually efficient at pulling cadmium out of the soil they grow in, and recent independent testing has flagged several sunflower-butter brands with single-serving cadmium loads above the California Proposition 65 warning level. Cadmium accumulates in the kidneys and skeleton over years. Occasional use is unlikely to matter; a small body eating multiple tablespoons most days is the realistic concern. If sunflower butter is the household staple — usually because of a peanut allergy — rotate brands and watch the third-party testing reports.

Advanced kidney disease. Nut butters are concentrated in potassium and phosphorus. If you're on a clinically managed renal diet, the portion size has to come from your dietitian, not from this entry.

Other options on the same shelf

The honest answer is that the strongest alternative to nut butter is the whole nut, when chewing isn't a problem and the spread isn't the point. The almond in your hand has more satiety per calorie, releases fewer calories than the label claims, and keeps blunting your blood sugar past the meal you ate it at. Use butter when you want a spread (toast, oats, fruit), a smoothie thickener, or a way to give a toddler or an older relative the same micronutrients without the chewing demand.

Within the butter shelf, the choice is mostly about household constraints. Plain peanut butter is cheapest by a wide margin and the most-studied. Almond and cashew butter cost roughly twice as much, taste milder, and carry more vitamin E. Tahini is the strongest pick for a peanut-allergic household and brings the largest calcium dose per serving. Sunflower-seed butter is the safe-school-snack option but carries the cadmium concern above.

Compared to what nut butter typically replaces — butter, margarine, jam, chocolate-hazelnut spread — every two-ingredient nut or seed butter wins on the things a blood test would care about: more protein, less saturated fat, more minerals, less added sugar.

Related threads worth pulling: whole nuts and seeds as a daily snack (the stronger version of this story); early peanut introduction in infants, where smooth peanut butter thinned with water or breastmilk has become standard since the LEAP trial; reading nutrition labels generally, where the "two ingredients, both of which are the actual food" rule extends past the spread shelf to yoghurt, bread, and granola.

Substance and claimed effects

This entry covers ground nut and seed spreads — peanut butter, almond butter, cashew butter, tahini (sesame), and sunflower-seed butter — eaten as a regular food rather than as a treat. The substance is the butter form, mechanically distinct from the whole nut or seed: cell walls are ruptured, fat is released from its intracellular matrix, and the food becomes a homogeneous lipid-protein paste. Effects under review: satiety and within-meal intake control, postprandial glucose response, blood-lipid markers (LDL-C, apoB, triglycerides), caloric density and weight-trajectory consequences, and micronutrient delivery. Common label additions worth treating as part of the substance because they shift its profile materially: added sugar, salt, and stabilising fats (palm oil, fully hydrogenated vegetable oil).

Evidence by addressing question

mechanism

The whole-nut versus butter distinction is the central biophysics. In a whole almond, ~50% of its fat is sequestered inside intact parenchymal cell walls; in faecal-recovery studies that lipid passes through partially undigested, recovered as identifiable cellular fragments. Grinding into butter ruptures the cell walls and the fat becomes fully bioaccessible. Measured metabolizable energy of whole natural almonds is 4.4 kcal/g and chopped roasted almonds 5.0 kcal/g — both significantly below the 6.0 kcal/g predicted by Atwater factors — whereas almond butter delivers 6.5 kcal/g, statistically indistinguishable from prediction Gebauer 2016, Novotny 2012. A 30 g serving of almonds is thus ~50 kcal in whole form and ~195 kcal in butter form — a ~25% caloric uplift the consumer almost never registers.

Satiety mechanics shift in parallel. Whole-nut consumption activates oro-pharyngeal stretch and chewing signals: in Cassady 2009 healthy adults chewing 55 g of almonds 40 times before swallowing reported lower hunger and altered GLP-1 and CCK responses compared with chewing 10 times. Butter bypasses that mastication signal: smaller hunger suppression and larger hunger rebound at 180 minutes have been observed when peanuts are eaten as butter rather than whole. The lipid-protein matrix still slows gastric emptying — butters remain more satiating per kcal than carbohydrate snacks — but the chewing-mediated upregulation of fullness is partly forfeited.

Postprandial glucose: the fat-protein-fibre combination of nut butters blunts the glycaemic response to co-ingested carbohydrate. The mechanism is delayed gastric emptying, slower starch hydrolysis, and modest first-phase insulin enhancement from leucine and arginine in nut protein. In Mori 2011, both almond butter and whole almond significantly attenuated postprandial AUC glucose at the meal they were co-ingested with; whole almonds additionally extended the effect into the second meal and across the day, butter did not — consistent with the slower-digesting cell-wall-protected lipid in the whole nut acting as a continued brake.

Lipid-marker mechanism: monounsaturated fatty acids (oleic, dominant in almond and cashew butter; ~50% of peanut butter fat), phytosterols (~100–200 mg per 100 g in tree-nut butters), and viscous fibre displace dietary saturated fat and reduce intestinal cholesterol absorption. ApoB-bearing lipoprotein particles (LDL, VLDL remnants) fall in tandem.

Micronutrient mechanism: butters are dense vehicles for several minerals the typical diet undersupplies. Two tablespoons of peanut butter deliver ~57 mg magnesium (~14% DV) and ~7 g protein; two tablespoons of tahini deliver ~128 mg calcium (~10–12% DV) plus sesame lignans (sesamin, sesamolin); almond butter contributes ~7 mg vitamin E (~50% DV) per 30 g. Mineral bioavailability is partially attenuated by phytate and (for sesame) oxalate, but absolute delivery still exceeds the bread or jam it usually replaces.

evidence

Lipid endpoints — RCT-grade. A 61-trial meta-analysis of controlled tree-nut feeding studies found pooled reductions of total cholesterol −4.7 mg/dL, LDL-C −4.8 mg/dL, apoB ~−3.7%, and triglycerides −2.2 mg/dL, dose-dependent up to ~60 g/day Del Gobbo 2015. Most of these trials used whole nuts; the subset using nut paste or butter showed the same direction and magnitude. In Berryman 2015, 42 g/day of almonds (whole or ground) for 6 weeks reduced LDL-C by ~5 mg/dL versus an isocaloric muffin control in adults with elevated LDL — and reduced central abdominal fat by ~0.07 kg despite calorie matching.

Cardiovascular and mortality cohorts. PREDIMED randomised 7,447 high-CV-risk adults to a Mediterranean diet supplemented with 30 g/day mixed nuts (walnuts, almonds, hazelnuts — whole, not butter) versus low-fat control; the nut arm cut composite major cardiovascular events by ~28% over a median 4.8 years Estruch 2018. Bao 2013 (NHS + HPFS, n≈119,000) found a dose-response inverse association between nut consumption and all-cause mortality (HR 0.80 for ≥7 servings/week vs. none). Aune 2016 meta-analysed 20 prospective studies and reported ~22% lower all-cause mortality at 28 g/day intake.

The peanut-butter-specific anomaly. In the NIH-AARP cohort (n=566,398, 15.5 y follow-up), tree nuts and peanuts were inversely associated with all-cause mortality, but peanut butter was not Luu 2015. Jiang 2002 in the NHS (women) found peanut butter consumption was associated with lower T2D incidence (RR 0.79 for ≥5 servings/week vs. rare/none), parallel to whole nuts. The most plausible reading of the divergence: nut-butter consumers in the US are mixing health-marker confounders (added-sugar peanut butter on bread, often with jelly), and the residual confounding from refined-carb co-ingestion offsets nut benefit at the population level. RCT-level lipid data on nut paste vs. nut do not show a divergence.

Glycaemia. Josse 2007 dose-response demonstrated almonds at 30 g, 60 g, and 90 g progressively flattened the glycaemic response to a 50 g carbohydrate meal in healthy adults. Mori 2011 showed almond butter shares the within-meal benefit but loses the daylong second-meal benefit whole almonds confer.

Body weight. Mattes 2008 reviewed 31 nut-feeding trials and reported that regular nut intake — added without explicit calorie compensation — produces, on average, less weight gain than the prescribed energy uplift predicts, attributable to incomplete fat absorption (whole nuts), satiety-driven downstream compensation, and a small thermogenic uplift. The mechanism that drives this — incomplete fat absorption — is the one most attenuated when nuts are ground into butter, so the body-weight reassurance from whole-nut trials transfers weakly to butter consumed by the spoon.

protocol

The action is mostly substitution and label-reading, not a dose. The intake that approximates the cohort and RCT evidence is ~28–60 g/day (1–2 standard tablespoons of peanut butter is ~16–32 g) on a regular basis, used as a spread or stirred into oats/yoghurt/fruit.

Label criteria for a product that resembles the substance in the literature:

Ingredient list: nut/seed only, or nut/seed plus salt. Two-ingredient or one-ingredient products. The visible oil layer on top is a feature, not a defect — it is the unmodified nut oil that the no-stabilizer brands let separate.
No added sugar (sucrose, glucose-fructose syrup, honey, evaporated cane juice). Mainstream commercial peanut butter (Skippy/Jif-class) routinely carries 2–3 g added sugar per 32 g serving.
No palm oil or fully hydrogenated vegetable oil. These are stabilizers added to prevent the oil-protein separation; they do not alter the nutrient quality of the nuts themselves, but they substitute saturated palm fat for the nut's monounsaturated fat and (for palm) bring deforestation externalities.
For peanut butter specifically: storage in a cool, dry place; rancidity and aflatoxin both rise with heat and humidity. Once opened, refrigeration extends shelf life.

For glycaemic benefit, pair the butter with the high-carb item (toast, fruit, oats) rather than eating it solo. For satiety, prefer the whole nut where the option exists; reserve butter for the contexts where the whole nut won't work (toddler, no-teeth elderly, baking, smoothies, energy bars).

contraindications

Tree-nut and peanut allergy: type-1 IgE-mediated reactions can be life-threatening; peanut allergy affects ~1–2% of children and ~0.5–1% of adults in Western populations. Cross-reactivity within the legume family is uncommon for adults but real for some children. Tahini and sunflower butter are alternatives for nut-allergic households.

Aflatoxin in peanut products: Aspergillus flavus contaminates peanut crops under hot, humid storage; aflatoxin B1 is a class-1 hepatocarcinogen Williams 2004. US FDA action level is 20 ng/g total aflatoxins; US commercial peanut butter is routinely tested and rarely exceeds it, but global regulatory variation is wide and quantitative risk modelling suggests current standards may be insufficient in low-resource settings Wu 2018. In high-income settings the population-level HCC contribution from peanut butter consumption is small.

Cadmium in sunflower-seed butter: sunflowers are accumulators of cadmium from soil; independent testing has flagged several sunflower-butter brands with single-serving cadmium levels above the California Proposition 65 warning threshold. Cadmium is a WHO class-1 carcinogen with renal and skeletal toxicity at chronic exposure. Daily multi-tablespoon consumption is the realistic risk; occasional use is unlikely to be material.

Kidney disease: high potassium and phosphorus content of nut butters is relevant for advanced CKD; clinician guidance on portion control.

misconceptions

The dominant misconception is that nut butters and whole nuts are interchangeable. They are nutritionally similar but biophysically different: Gebauer 2016 demonstrates the ~25% delivered-calorie gap. A consumer reading the back of a jar sees the Atwater calorie estimate (which is right for butter) but compares it mentally to the whole-nut calorie estimate (which is ~25% wrong, in their favour). Second misconception: the "natural" label is meaningful. FDA does not regulate it; reading the ingredient list is the only useful gate.

Third: the oil layer is harmful or rancid. The separated oil is the nut's native unsaturated fat — palm oil and hydrogenated additions are precisely what prevents this layer from forming, by substituting more saturated stabilizers. Stir, refrigerate, eat.

alternatives

The relevant alternative for most readers is the whole nut, which beats butter on satiety, calorie absorption, and (for almonds specifically) prolonged glycaemic benefit. The relevant alternative on the spread shelf is butter (dairy), margarine, jam, or chocolate-hazelnut spread — all of which the nut butter dominates on protein, micronutrients, and fatty-acid profile. Tahini is the strongest alternative for the nut-allergic household.

failure-modes

Three common failures. (1) Calorie creep: high palatability + high energy density + low chewing demand makes spoon-from-jar grazing a real pattern. The 195 kcal that a 30 g serving of almond butter delivers is invisible relative to the same mass of whole almonds (~50 kcal absorbed). Portioning by tablespoon, not by spoon-feel, prevents most of this. (2) Choosing the wrong product: a sweetened/palm-oiled commercial peanut butter recapitulates the macro profile of a candy bar. (3) Replacing whole nuts with butter for "convenience" — a substitution that costs the satiety and energy-absorption benefits documented in Cassady 2009 and Gebauer 2016.

practicalities

Two-ingredient peanut butter retails ~$5–$10 per 500 g jar in the US; almond butter and cashew butter ~$10–$15; tahini ~$8–$15. At one tablespoon per day, annual cost is ~$30–$80, well inside the "trivial cost" band. Shelf life unopened: 6–12 months for natural butter; opened and refrigerated: 3–4 months. The visible oil layer reincorporates with a fork; storing jars upside down for a week before opening helps even distribution.

The credibility range

Optimist case

Whole-nut consumption has some of the strongest mortality, cardiovascular, and lipid evidence in nutrition science (PREDIMED RCT, NHS/HPFS cohorts at n > 100,000, 61-trial lipid meta-analysis). Nut butters share the macronutrient profile, the lipid effect at RCT-level, the glycaemic-blunting effect, and the micronutrient delivery. Substituting two tablespoons of plain nut butter for two tablespoons of margarine, jam, or chocolate-hazelnut spread is a strict upgrade on every measured cardiometabolic axis. The peanut-butter-not-associated-with-mortality finding in NIH-AARP is almost certainly a label-reading confound (sugary commercial PB on white bread is the typical US PB exposure), not a per-substance verdict on plain nut butter.

Skeptic case

The signature mechanism behind the whole-nut weight-neutrality finding — incomplete fat absorption from intact cell walls — is mostly ablated by grinding. Gebauer 2016 is unambiguous on this. The satiety advantage of mastication (Cassady 2009) is partly forfeited. The peanut-butter-specific cohort signal (no mortality benefit in NIH-AARP, while peanuts themselves benefit) deserves to be taken at face value at the level of population behaviour: most consumers do not select two-ingredient butter, do not use it as a strict substitute for an upstream less-healthy spread, and do exhibit calorie creep. The strongest skeptic position is not "nut butters are bad" — it is that the catalogue-level recommendation has to be specific to the two-ingredient product and the substitution context, or the benefit disappears.

Author's call

Plain (two-ingredient) nut and seed butters earn a modest endorsement: real, replicable benefit on lipid markers and postprandial glucose; meaningful micronutrient delivery; high satiety per kcal versus competing spreads; convenient vehicle for the broader whole-nut habit when the whole nut won't work. The catalogue-level scoring should be sober rather than enthusiastic — it is not a transformative intervention, the whole nut is usually better, and the product-selection / portion-control failure modes are realistic enough to be load-bearing. Evidence is strong (4) on the underlying nut literature; controversy is low (1) at the per-substance level once added-sugar and palm-oil products are excluded.

Stakeholder and incentive map

Commercial. Almond Board of California, National Peanut Board, and equivalent commodity bodies fund a meaningful share of nut research; the mechanism is open and the published work is not obviously biased, but the publication agenda skews toward favourable endpoints.
Mainstream brands. Skippy, Jif, Smucker's etc. profit from the sugared/stabilized formulation that confounds the cohort data; their incentive runs against the "read the label" framing this entry takes.
Cardiometabolic guidelines. AHA, ESC, and PREDIMED-derived Mediterranean-diet guidance broadly endorse nuts at ~30 g/day; they generally do not distinguish whole vs. butter form.
Allergy advocacy. Tahini and sunflower-butter manufacturers are the natural beneficiaries of the household-with-allergic-child use case.

Population variability

Baseline diet quality. Lipid benefit is largest when nut butter displaces saturated-fat-rich spreads (butter, margarine); negligible-to-negative when added on top of an already saturated-fat-replete diet.
Glucose-tolerant vs. impaired. Postprandial-glucose effect is larger in impaired/diabetic subjects Mori 2011; subtle in metabolically healthy adults.
Energy needs. For active or underweight adults the caloric density is a feature; for sedentary calorie-restricting adults it is the leading failure mode.
Children with peanut allergy risk. Early peanut introduction (post-LEAP trial era) is now standard recommendation; smooth peanut butter thinned with water/breastmilk is one of the canonical vehicles for sustained early exposure. Outside this entry's primary scope but worth flagging.
Households with toddler or allergy. Tahini and sunflower butter substitute well; cadmium load in sunflower butter argues against daily multi-tablespoon use by small bodies.

Knowledge gaps

Long-term (decade-scale) cohort data isolating plain nut butter from sugared commercial nut butter does not exist; the NIH-AARP and NHS measures lump them.
Head-to-head RCT of nut butter vs. equivalent gram-weight whole nut at constant prescribed intake, with body composition, postprandial glucose, satiety hormones, and lipids as primary endpoints — partial data from Mori 2011 and Gebauer 2016, but no large pragmatic trial.
Sunflower-butter cadmium exposure has not been characterised in a regulatory-grade dietary-intake study; consumer-lab evidence drives current concern.
The relative contribution of sesame lignans to tahini's lipid effect (vs. its MUFA/PUFA content alone) is not well separated in trials.

Scope coverage relative to the brief: the description named satiety, postprandial glucose, lipid markers, caloric density / intake control, and micronutrient intake. All five are addressed across mechanism / evidence / failure-modes / contraindications. Added sugar, salt, and palm oil are folded into protocol and misconceptions as label-reading guidance rather than a separate section.

Hard scoring calls:

Longevity at 2. The strong cohort and PREDIMED data are for whole nuts; Luu 2015 found peanut butter specifically did not show the mortality signal in NIH-AARP. I attribute the divergence to the typical-American-PB exposure (sugared, on white bread) rather than to the butter form per se — RCT lipid data on butter form is in line with whole nuts. A 2 honestly splits the difference; a 3 would overclaim, a 1 would underclaim.
Health_short_term at 2, not 3. Postprandial glucose and satiety effects are real but modest; the typical reader does not notice a transformation week-to-week. Reserved 3 for entries where the felt-experience case is stronger.
Beauty_cumulative at 1. Honest acknowledgement that lipid and micronutrient improvements run downstream to skin/hair, but unobservable without a blood test. Could be defended as 0; left at 1 because the magnesium and vitamin E delivery is meaningful for a Western diet.
Energy at 1, focus/mood/sleep at 0. No serious evidence base for the butter form on these axes; declined to inflate.

Dream narrative: written despite the overall score being below 40 (~29), because the entry has a clear relief lever (the "you're being subtly conned by the mainstream jar" framing). Used to shape the dek and tagline; opening paragraph runs straight, since the dream tier here is light.

Excluded from the article body:

Detailed allergen-introduction protocol for infants (LEAP-trial-era guidance) — flagged in out-of-scope; warrants its own entry.
Phytates and oxalates as mineral-absorption modifiers — mentioned briefly in the research dossier; would clutter the article without changing the reader's action.
Stakeholder / commodity-board funding politics — relevant for the research dossier but not load-bearing for the reader.

Separate-entry candidates: Whole nuts as a daily snack (the stronger sibling of this entry); Early peanut introduction for infants; Reading ingredient lists as a general literacy entry.

Future-link targets once they exist: whole-nuts entry, infant-peanut-introduction entry, label-reading entry, Mediterranean-diet pattern entry.